Sandbox/intraabdominal: Difference between revisions
< Sandbox
No edit summary |
|||
Line 245: | Line 245: | ||
{| | {| | ||
| valign=top | | | valign=top | | ||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: | <div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 47px; line-height: 47px; width: 225px; background: #A1BCDD; text-align: center;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
'''Multidrug resistant gram-negative bacilli''' | '''Multidrug resistant gram-negative bacilli''' | ||
Line 269: | Line 269: | ||
</div> | </div> | ||
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: | <div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 47px; line-height: 47px; width: 225px; background: #A1BCDD; text-align: center;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
'''''Pseudomonas aeruginosa''''' '''>20% resistant to ceftazidime''' | '''''Pseudomonas aeruginosa''''' '''>20% resistant to ceftazidime''' | ||
Line 294: | Line 294: | ||
| valign=top | | | valign=top | | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible- | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table07" style="background: #FFFFFF;" | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}} | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Carbapenem | ||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Meropenem]] 1 g IV q8h''''' | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]]/[[Cilastatin]] 500 g IV q6h or 1 g q8h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doripenem]] 500 g IV q8h''''' | ||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Cephalosporin-based | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftazidime]] 200-300 mg/kg/day IV q12h''''' | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 200-300 mg/kg/day IV q12h''''' | ||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h''''' | ||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Penicillin-based | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Piperacillin]]-[[Tazobactam]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Piperacillin]]-[[Tazobactam]] 3.375 g q4h or 4.5 g q6h ''''' | ||
|- | |- | ||
|} | |} |
Revision as of 17:14, 12 June 2014
Initial Empiric Treatment of Extra-biliary Community-acquired Complicated Intra-abdominal Infection
▸ Click on the following categories to expand treatment regimens.
Pediatric patients ▸ Single agent ▸ Combination Adults, mild-to-moderate severity ▸ Single agent ▸ Combination Adults, high risk or severity ▸ Single agent ▸ Combination |
|
Empiric Antimicrobial Therapy for Health Care-Associated Complicated Intra-abdominal Infection
▸ Click on the following categories to expand treatment regimens.
Multidrug resistant gram-negative bacilli ▸ Regimen ESBL-Enterobacteriaceae ▸ Regimen Pseudomonas aeruginosa >20% resistant to ceftazidime ▸ Regimen MRSA ▸ Regimen |
|